Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
NFE2L2 mutation
i
Other names:
NFE2L2, Nuclear Factor Erythroid 2 Like 2, Nuclear Factor Erythroid 2-Related Factor 2, NF-E2-Related Factor 2, HEBP1, Nrf-2, NRF2, Nuclear Factor Erythroid Derived 2 Like 2, Nuclear Factor (Erythroid-Derived 2)-Like 2, Nuclear Factor Erythroid-Derived 2-Like 2, Nuclear Factor Erythroid 2-Like 2, NFE2-Related Factor 2, IMDDHH
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4780
Related biomarkers:
Expression
Mutation
‹
›
Associations
(7)
News
Trials
Search handles
@AndresFCardonaZ
@DrewMoghanaki
@HenningWillers
@Latinamd
@MartinReck2
@StephenVLiu
@UmutDisel
@VivekSubbiah
@dmarinelli93
Search handles
@AndresFCardonaZ
@DrewMoghanaki
@HenningWillers
@Latinamd
@MartinReck2
@StephenVLiu
@UmutDisel
@VivekSubbiah
@dmarinelli93
Filter by
Latest
12ms
#OpenAccess in @CR_AACR from @LabDeNicola @MoffittNews Distinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression https://t.co/ZzixrBgvec Autochthonous models that genocopy human KEAP1 & NRF2 mutations demonstrate context dependent role in multistep process (@Aiims1742)
12 months ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
12ms
Targeting NFE2L2/KEAP1 Mutations in Advanced NSCLC With the TORC1/2 Inhibitor TAK-228 https://t.co/Y5n7ni3SOj (@AndresFCardonaZ)
12 months ago
Metastases
|
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
|
sapanisertib (CB-228)
over1year
Currently recruiting for phase II trial led by @RachelSanbornMD for patients with stage IV NFE2L2-mutated or wild-type #sqNSCLC whose disease has progressed while taking or after receiving at least two prior systemic therapies. More info: https://t.co/DIHjuexuXz. #lcsm (@ChilesResearch)
over 1 year ago
Clinical
|
NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
NFE2L2 mutation
over1year
Targeting chemo resistant NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the #TORC1/2 inhibitor TAK-228 https://t.co/QFJNCi5s81 via @JTOonline ➡️Ph II TAK-228 efficacy in NFE2L2 + ➡️ORR 25% , mPFS 8.9 mos (@Latinamd)
over 1 year ago
Clinical
|
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
|
sapanisertib (CB-228)
over1year
Targeting NFE2L2/KEAP1 mutations in advanced non-small cell lung cancer with the TORC1/2 inhibitor TAK-228 https://t.co/z0phbiuZ2P (@VivekSubbiah)
over 1 year ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
|
sapanisertib (CB-228)
over1year
New potential targeted therapy for squamous NSCLC? TAK-228 (TORC1/2 inhibitor) in NRF2 activated NSCLC @JTOonline. In NFE2L2 mutant squamous NSCLC, RR 25% (3 out of 12) with impressive mPFS of 8.9m. Looking forward to larger studies. #LCSM https://t.co/wSSXfgCL8V (@StephenVLiu)
over 1 year ago
NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
NFE2L2 mutation
|
sapanisertib (CB-228)
almost2years
PS Interestingly KEAP1/NRF2 mutations that likely associate with radioresistance are common in lung squamous cell cancer (SCC), supporting the notion to profile those histologies as well @max_diehn @michaelsbinkley (@HenningWillers)
almost 2 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
almost2years
Nice title. However, I'm having trouble understanding why there is no NRF2 mutation in these images. It is seen in 15% of squamous lung cancers.@Dr_R_Kurzrock @BenWestphalen @geoff_oxnard @SewantiLimaye @oncologician @christine_lovly (@UmutDisel)
almost 2 years ago
NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
NFE2L2 mutation
over2years
@max_diehn summarizing pioneering @StanfordRadOnc work on KEAP1/NRF2 mutations as predictors of recurrence after #radiotherapy in #lungcancer Published in @CD_AACR in 2020 New: RSI not predictive in their cohorts (though patient number is small) #RadRes21 #radbio #LCSM (@HenningWillers)
over 2 years ago
Clinical
|
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
over2years
🌟Online now @LungCaJournal a review covering the role of KEAP1/NRF2 (NFE2L2) mutations in NSCLC – Fuel for a superresistant phenotype? by @MartinReck2 #LungCancer #LCSM Find it here 👇 https://t.co/Gd8QtVWyf0 (@LungCaJournal)
over 2 years ago
Review
|
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
over2years
KEAP1/NRF2 (NFE2L2) mutations in NSCLC – Fuel for a superresistant phe... https://t.co/pT5xUABzjG Just out - perhaps some new information for understanding the complexity of lung cancer! (@MartinReck2)
over 2 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
almost3years
REMINDER: stage I NSCLC with KEAP1/NFE2L2 mutations might not be eradicated w/ SBRT. The operative word is "might" and, of course, larger cohorts are needed to confirm this finding. Fortunately, resection can overcome such resistance. #radonc @BrendonStilesMD @max_diehn (@DrewMoghanaki)
almost 3 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
almost3years
Watching the #AACR21 session on Molecular Determinants of Radiation Resistance? ICYMI in @CD_AACR - KEAP1–NFE2L2 mutations predict #LungCancer radiation resistance that can be targeted by glutaminase inhibition @michaelsbinkley @max_diehn @Stanford https://t.co/guebKeq9Rn (@ElizSMcKenna)
almost 3 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
almost3years
Attending the #AACR21 #Radiation Science & Medicine Working Group Town Hall? ICYMI in @CD_AACR - KEAP1–NFE2L2 mutations predict #LungCancer radiation resistance that can be targeted by glutaminase inhibition @michaelsbinkley @max_diehn @Stanford https://t.co/wqhSD0WyJ7 (@ElizSMcKenna)
almost 3 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
3years
KEAP1–NFE2L2 mutations predict #LungCancer radiation resistance that can be targeted by glutaminase inhibition. @michaelsbinkley @max_diehn @Stanford #RadOnc #Radiotherapy #AACRrsm21 https://t.co/bpkDVKfat2 (@CD_AACR)
3 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
3years
2/n KEAP1+NRF2 mutations, which are remarkably common in #lungcancer, recently gained attention as predictors of radioresistance ➡️ potential to enter clinical practice in the not too distant future? Data already discussed on #Twitter as part of @ASTRO_org +@RRS_RadRes meetings (@HenningWillers)
3 years ago
Clinical
|
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
3years
SCI leader Max Diehn and colleagues analyzed patients with localized #nonsmallcelllungcancer and identified KEAP1 and NFE2L2 mutations as being predictive of high rates of local recurrence (LR) after radiotherapy but not surgery. https://t.co/kDQNFY3b9R @max_diehn @CD_AACR #nsclc (@SCIDirector)
3 years ago
Clinical
|
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
over3years
From the December issue: KEAP1–NFE2L2 mutations predict #LungCancer radiation resistance that can be targeted by glutaminase inhibition. @michaelsbinkley @max_diehn @Stanford #RadOnc #Radiotherapy https://t.co/0pJekToND3 (@CD_AACR)
over 3 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
over3years
Check out the paper featured on the cover of this month’s Cancer Discovery: KEAP1–NFE2L2 mutations predict #LungCancer radiation resistance that can be targeted by glutaminase inhibition. @michaelsbinkley @max_diehn @Stanford #RadOnc #Radiotherapy https://t.co/bsnNEGrUuU (@CD_AACR)
over 3 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
over3years
ICYMI: KEAP1–NFE2L2 mutations predict #LungCancer radiation resistance that can be targeted by glutaminase inhibition. @michaelsbinkley @max_diehn @Stanford #RadOnc #Radiotherapy https://t.co/1W7KeWNVhZ (@CD_AACR)
over 3 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
over3years
November is #LungCancerAwarenessMonth: KEAP1–NFE2L2 mutations predict #LungCancer radiation resistance that can be targeted by glutaminase inhibition. @michaelsbinkley @max_diehn @Stanford #RadOnc #Radiotherapy https://t.co/jO4qbkBIsZ (@CD_AACR)
over 3 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
over3years
Check out this great study about KEAP1/NFE2L2 mutations and radioresistance in NSCLC by @michaelsbinkley @max_diehn @AshAlizadeh and colleagues in @CD_AACR! Congratulations to all! (@imsmd)
over 3 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
over3years
Just published #OnlineFirst: KEAP1–NFE2L2 mutations predict #LungCancer radiation resistance that can be targeted by glutaminase inhibition. @michaelsbinkley @max_diehn @Stanford #RadOnc #Radiotherapy https://t.co/TsZkKhQbZ5 (@CD_AACR)
over 3 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
over3years
Thrilled our paper showing KEAP1/NFE2L2 mutations predict for radiation resistance in NSCLC which may be overcome by glutaminase inhibition is in press (https://t.co/5od0W1JzWh). Grateful for mentorship by @max_diehn and all coauthors including Dr. Jeon. Towards precision RT (@michaelsbinkley)
over 3 years ago
KEAP1 (Kelch Like ECH Associated Protein 1) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2)
|
KEAP1 mutation • NFE2L2 mutation
over3years
Amazing talk at #RadRes2020 by @max_diehn as always. Mutation of KEAP1 or NRF2 are associated with clinical radioresistance after #radiotherapy or #SBRT in #lungcancer Other genes including KRAS and TP53 (and STK11?) did not predict radioresistance (though combos not explored) (@HenningWillers)
over 3 years ago
Clinical
|
KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • STK11 (Serine/threonine kinase 11) • KEAP1 (Kelch Like ECH Associated Protein 1)
|
KEAP1 mutation • NFE2L2 mutation
almost4years
KEAP1-NFE2L2 Mutations in NSCLC: Increased Awareness Needed @MaugeriSacca @JTOonline https://t.co/vNcBIQkxl6 (@dmarinelli93)
almost 4 years ago
KEAP1 (Kelch Like ECH Associated Protein 1)
|
KEAP1 mutation • NFE2L2 mutation
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login